Unichem Laboratories Ltd
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 6, 2027The maintenance fee for Process for the preparation of Rivaroxaban involving novel intermediate (US 11,891,384) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Recombinant Lectin Variants (US 11,965,003) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Aug 25 US 12,714,737 Recombinant Proteins, Compositions and Methods of Stabilization Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,118,924 | Process for the preparation of Apixaban and intermediates thereof In force · USPTO record | In force | USPTO record | |
| US 10,208,036 | Process for the preparation of Apixaban and intermediates thereof In force · USPTO record | In force | USPTO record | |
| US 11,034,683 | Process for the preparation of rivaroxaban involving novel intermediate In force · USPTO record | In force | USPTO record | |
| US 11,510,909 | Pharmaceutical composition of apixaban In force · USPTO record | In force | USPTO record | |
| US 10,836,730 | Process for preparation and purification of vortioxetine hydrobromide In force · USPTO record | In force | USPTO record | |
| US 10,919,855 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide In force · USPTO record | In force | USPTO record | |
| US 11,020,390 | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide In force · USPTO record | In force | USPTO record | |
| US 11,266,628 | Pharmaceutical Compositions of Apremilast In force · High confidence | In force | High confidence | |
| US 11,891,384 | Process for the preparation of Rivaroxaban involving novel intermediate In force · USPTO record | In force | USPTO record | |
| US 11,965,003 | Recombinant Lectin Variants In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 11 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 2 abandoned · 9 no status recorded
Showing 1 to 10 of 17, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/828,436 | Protein for Treatment of Inflammatory Diseases | Sep 9, 2024 | Pending |
| 18/718,862 | Recombinant Protein for SARS-COV2 Disease | Dec 14, 2022 | Pending |
| 18/692,059 | Lectin-Drug Conjugates | Sep 30, 2022 | Pending |
| 18/691,412 | Recombinant Glycan Binding Proteins and Its Use | Sep 30, 2022 | Pending |
| 18/684,064 | Protein Compositions for the Treatment of Inflammatory Diseases | Aug 27, 2022 | Pending |
| 18/260,404 | Lectin Protein for Treatment and Prevention of Neurodegenerative Diseases | Jan 5, 2022 | Pending |
| 18/030,583 | Oct 6, 2021 | No status recorded | |
| 17/923,732 | Apr 28, 2021 | No status recorded | |
| 17/599,642 | Mar 28, 2020 | No status recorded | |
| 17/440,124 | Mar 4, 2020 | No status recorded |
10 of 17 applications shown.
Pro members see all 17 published applications.